Atopic dermatitis management with topical corticosteroids in children: own observations

Abstract

Atopic dermatitis is the most common chronic inflammatory skin disease in children, that significantly affects quality of life. Clinical manifestations are genetically determined and caused by skin barrier dysfunction and development of immune reactions. Atopic dermatitis is characterized by early onset, recurrence, and presence of treatment resistant forms. It is important to prescribe treatment that controls the symptoms and reduces the risk of severe forms of this disease. Topical corticosteroids are the mainstay of atopic dermatitis management, although the prolonged treatment can lead to development of side effects. The treatment option, that has high efficacy and high profile of safety, is the basis for disease remission and overcoming corticosteroid phobia. Methylprednisolone aceponate meets all criteria for topical corticosteroids and has high efficacy and high profile of safety. It can be recommended for patients with atopic dermatitis from the age of 4 months. This paper shows up-to-date data on methylprednisolone aceponate, that confirm the optimized efficacy/safety profile and minimal local or systemic adverse effects. Recent studies demonstrated the efficacy of new Russian product – methylprednisolone aceponate (Komfoderm K).